Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data

Abstract Background Patients with polycythemia vera (PV) have a higher mortality risk compared with the general population, primarily driven by cardiovascular disease, thrombotic events (TEs), and hematologic transformations. The goal of risk-adapted therapy in PV is prevention of TEs. Current treat...

Full description

Bibliographic Details
Main Authors: Dilan Paranagama, Philomena Colucci, Kristin A. Evans, Machaon Bonafede, Shreekant Parasuraman
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Experimental Hematology & Oncology
Subjects:
Anagrelide
Hydroxyurea
Interferons
Myeloproliferative disorders
Polycythemia vera
Online Access:http://link.springer.com/article/10.1186/s40164-018-0107-8

Internet

http://link.springer.com/article/10.1186/s40164-018-0107-8

Similar Items